The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, but the biotech’s stock jumped in premarket trading.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, but the biotech’s stock jumped in premarket trading.